A DRUG used for diabetes, which works in a similar way to Ozempic, has shown some promise in a clinical trial for early-stage Parkinson's disease.
The drug, lixisenatide, is a glucagon-like peptide-1 receptor agonist and compared to the placebo it has been found to help slow the progression of motor disability after 12 months in a small phase 2 trial.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Apr 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Apr 24
